Skip to main content
EDIT logo

Editas Medicine, Inc.

EDITNASDAQHealthcareBiotechnology

$2.35Today:- (-)1Y −35.28%

As of Oct 16, 2026 close

Market cap
$291.08M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.66$4.33
Volume (live)
-
Avg. volume (3M)
3.00M

Editas Medicine (EDIT) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Editas Medicine used $165.24M of cash in operating activities and spent $607.00K on capital expenditures. That left free cash flow of −$165.85M.

Editas Medicine Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Editas Medicine, Inc. (EDIT) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-160.06-237.09-153.22-220.43-192.50-115.98-133.75-109.95-120.32
Depreciation & Amortization5.285.816.066.345.053.962.833.252.68
Deferred Income Tax0.000.000.000.000.00-16.370.00-3.670.00
Stock Based Compensation10.0021.4219.8029.2943.4023.1627.2426.6023.36
Change in Working Capital-31.233.45-1.598.18-21.41-102.2265.9326.8970.66
Change in Accounts Receivable1.09-6.08-5.04-4.885.78-5.63-0.390.65-0.59
Change in Inventory0.000.000.000.00-3.35-5.6510.651.57-8.94
Change in Accounts Payable-2.89-2.29-1.494.37-1.140.860.271.78-1.52
Change in Other Working Capital5.721.781.60-0.721.66-5.6555.4022.8981.71
Other Operating Activities5.721.781.60-0.721.660.10-2.9311.1714.20
Net Cash from Operating Activities-165.24-210.28-132.18-177.35-163.80-179.84-40.67-45.71-9.42
Investing Activities
Capital Expenditures-0.61-8.83-4.72-4.12-7.98-7.16-6.17-4.75-2.06
Acquisitions0.270.000.000.0246.490.010.100.040.02
Purchases of Investments0.00-86.22-258.52-315.19-408.89-133.37-342.18-459.37-375.27
Sales/Maturities of Investments139.01257.19259.51433.35362.40325.03360.50411.00193.50
Other Investing Activities0.000.000.000.00-46.490.000.000.040.02
Net Cash from Investing Activities138.67162.15-3.73114.07-54.47-140.5212.25-53.09-183.81
Financing Activities
Debt Repayment-2.870.000.000.000.000.000.00-0.86-0.76
Common Stock Issued42.850.78117.081.28249.46224.12116.3476.79154.14
Other Financing Activities-2.8755.240.960.0032.6520.4015.4811.01155.30
Net Cash from Financing Activities40.4756.03118.041.28282.11224.12131.8286.94154.53
Summary
Net Change in Cash13.907.89-17.87-62.0063.84-96.24103.41-11.85-38.69
Cash at Beginning of Period135.42127.53145.40207.40143.56239.80136.40148.25186.94
Cash at End of Period149.32135.42127.53145.40207.40143.56239.80136.40148.25
Free Cash Flow-165.85-219.11-136.90-181.47-171.78-187.01-46.84-50.46-11.48

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Editas Medicine Cash Flow

What is Editas Medicine's free cash flow?

Editas Medicine had negative free cash flow of $165.85M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$165.24M minus $607.00K of capital expenditures.

How much does Editas Medicine spend on capital expenditures?

Editas Medicine spent $607.00K on capital expenditures in fiscal 2025, compared with $8.83M a year earlier.

Does Editas Medicine pay dividends or buy back shares?

Editas Medicine's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition